< Back to Inductees

Emma Parmee, D.Phil.

Emma Parmee is currently Head of the Discovery Chemistry organization at Merck Research Labs.  The organization is responsible for the delivery of small molecule drug candidates and includes Medicinal Chemistry, Structural Chemistry, Modeling & Informatics, Chemical Biology, and Screening Capabilities. 

Emma moved to Merck’s West Point facility in 2010, assuming the role of Discovery Chemistry Site Lead where she was responsible for chemistry efforts in Neuroscience, HIV, and Bone. In 2013 she was named Head of the Exploratory Chemistry group, focused on the development of small molecule tools and lead series to enable the validation and progression of innovative new targets into the pipeline.  And from 2016 to 2018 Emma led the Chemical Capabilities and Screening Group - a cross-functional department designed to bring together critical adjacent capabilities to accelerate innovation in strategy and maximize pipeline impact

Prior to her move to West Point, Emma was located in Rahway where she worked for nearly eighteen years in Cardiometabolic areas and contributed to several projects which demonstrated clinical POC.  She was also privileged to work on the DPP-4 inhibitor project and contribute to the discovery of Januvia for which she was awarded Thomas Alva Edison Patent Award from the R&D Council of NJ and the SCI Gordon E. Moore Medal for Innovation.  She is also the recipient of the 2018 ACS Medicinal Chemistry Division Award.  Her work has led to more than forty issued US patents and over fifty publications in peer-reviewed journals.

Emma came to Merck in 1992 after completing a NATO postdoctoral fellowship at MIT under Professor Satoru Masamune.  She obtained her D. Phil. Degree in 1990 at the University of Oxford, studying the total synthesis of milbemycin natural products.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org